

IDERA PHARMACEUTICALS, INC.

Form 8-K

June 08, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 7, 2006**

**IDERA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**001-31918**

(Commission File Number)

**04-3072298**

(IRS Employer  
Identification No.)

**345 Vassar Street,  
Cambridge, Massachusetts**

(Address of Principal Executive Offices)

**02139**

(Zip Code)

**(617) 679-5500**

Registrant's telephone number, including area code:

**n/a**

(Former Name or Former Address, if Changed Since Last  
Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 1.01. Entry into a Material Definitive Agreement.

SIGNATURE

---

**Table of Contents**

**Item 1.01. Entry into a Material Definitive Agreement.**

On June 7, 2006, at the 2006 annual meeting of stockholders of Idera Pharmaceuticals, Inc. (the Registrant), the Registrant's stockholders approved an amendment to the Registrant's 2005 Stock Incentive Plan increasing the number of shares of the Registrant's common stock issuable under that plan from 5,000,000 to 9,000,000 and an amendment to the Registrant's 1995 Employee Stock Purchase Plan increasing the number of shares of the Registrant's common stock issuable under that plan from 500,000 to 1,000,000. These amendments became effective upon stockholder approval.

---

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDERA PHARMACEUTICALS, INC.

Date: June 8, 2006

By: /s/ Robert G. Andersen  
Robert G. Andersen  
Chief Financial Officer and Vice  
President of Operations